Paradigm Biocapital Advisors LP Immatics N.V. Transaction History
Paradigm Biocapital Advisors LP
- $2.47 Billion
- Q2 2024
A detailed history of Paradigm Biocapital Advisors LP transactions in Immatics N.V. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 3,421,965 shares of IMTX stock, worth $40.1 Million. This represents 1.61% of its overall portfolio holdings.
Number of Shares
3,421,965
Previous 2,818,908
21.39%
Holding current value
$40.1 Million
Previous $29.6 Million
34.22%
% of portfolio
1.61%
Previous 1.11%
Shares
5 transactions
Others Institutions Holding IMTX
# of Institutions
99Shares Held
76.6MCall Options Held
571KPut Options Held
210K-
Rtw Investments, LP New York, NY10MShares$117 Million1.94% of portfolio
-
Wellington Management Group LLP Boston, MA9.54MShares$112 Million0.02% of portfolio
-
Perceptive Advisors LLC New York, NY8.09MShares$94.9 Million2.72% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD7.43MShares$87.2 Million0.05% of portfolio
-
Baker Bros. Advisors LP New York, NY6.44MShares$75.6 Million1.0% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $894M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...